MacLean Hall

1.2k total citations
21 papers, 811 citations indexed

About

MacLean Hall is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, MacLean Hall has authored 21 papers receiving a total of 811 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in MacLean Hall's work include Immunotherapy and Immune Responses (13 papers), Cancer Immunotherapy and Biomarkers (13 papers) and CAR-T cell therapy research (12 papers). MacLean Hall is often cited by papers focused on Immunotherapy and Immune Responses (13 papers), Cancer Immunotherapy and Biomarkers (13 papers) and CAR-T cell therapy research (12 papers). MacLean Hall collaborates with scholars based in United States and United Kingdom. MacLean Hall's co-authors include Amod A. Sarnaik, Shari Pilon‐Thomas, Vernon K. Sondak, Jeffrey S. Weber, Keiran S.M. Smalley, Inna V. Fedorenko, Keith T. Flaherty, Kim H.T. Paraiso, Jane L. Messina and Liliana Cantini and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

MacLean Hall

19 papers receiving 805 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
MacLean Hall United States 9 637 399 307 67 56 21 811
Earl Avramis United States 12 711 1.1× 457 1.1× 347 1.1× 100 1.5× 38 0.7× 15 986
A. Ribas United States 14 478 0.8× 191 0.5× 286 0.9× 48 0.7× 33 0.6× 41 598
Virginia Picasso Italy 12 400 0.6× 197 0.5× 314 1.0× 101 1.5× 34 0.6× 16 661
Lisa Cucolo United States 3 668 1.0× 585 1.5× 345 1.1× 114 1.7× 14 0.3× 4 1.0k
Megan Duggan United States 14 326 0.5× 361 0.9× 222 0.7× 52 0.8× 29 0.5× 25 631
Teofila Seremet Belgium 15 630 1.0× 387 1.0× 351 1.1× 148 2.2× 24 0.4× 35 928
John Jakob United States 9 557 0.9× 111 0.3× 536 1.7× 145 2.2× 90 1.6× 13 808
Viviana Bozón United States 11 525 0.8× 377 0.9× 195 0.6× 58 0.9× 18 0.3× 28 662
Petranel T. Ferrão Australia 6 206 0.3× 203 0.5× 336 1.1× 60 0.9× 18 0.3× 8 629
Marcello Curvietto Italy 10 434 0.7× 239 0.6× 180 0.6× 108 1.6× 27 0.5× 29 618

Countries citing papers authored by MacLean Hall

Since Specialization
Citations

This map shows the geographic impact of MacLean Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MacLean Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MacLean Hall more than expected).

Fields of papers citing papers by MacLean Hall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by MacLean Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MacLean Hall. The network helps show where MacLean Hall may publish in the future.

Co-authorship network of co-authors of MacLean Hall

This figure shows the co-authorship network connecting the top 25 collaborators of MacLean Hall. A scholar is included among the top collaborators of MacLean Hall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with MacLean Hall. MacLean Hall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hall, MacLean, et al.. (2024). 887 The chromosome 19 microRNA cluster facilitates TIL-based immune evasion in human melanoma. Regular and Young Investigator Award Abstracts. A1001–A1001. 1 indexed citations
3.
Beatty, Matthew, MacLean Hall, John E. Mullinax, et al.. (2024). 460 Enrichment of neoantigen reactive tumor infiltrating lymphocytes (TIL) in gastric cancer. Regular and Young Investigator Award Abstracts. A520–A520. 1 indexed citations
4.
Beatty, Matthew, MacLean Hall, Larissa A. Pikor, et al.. (2023). 346 Expansion and identification of neoantigen reactive tumor infiltrating lymphocytes (TIL) from metastatic colorectal (CRC) and GI cancers. SHILAP Revista de lepidopterología. A395–A395.
5.
Khaled, Mariam Lotfy, Brittany Evernden, Zhihua Chen, et al.. (2023). Abstract 1192: Branched-chain keto acids exert an immune-suppressive and neurodegenerative microenvironment in CNS leptomeningeal lymphoma. Cancer Research. 83(7_Supplement). 1192–1192. 1 indexed citations
6.
Aydın, Ahmet Murat, MacLean Hall, Matthew Beatty, et al.. (2021). Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. International Immunopharmacology. 94. 107481–107481. 26 indexed citations
7.
Mullinax, John E., MacLean Hall, Matthew Beatty, et al.. (2021). Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function. Journal of Immunotherapy. 44(2). 63–70. 34 indexed citations
8.
Innamarato, Patrick, Krithika N. Kodumudi, MacLean Hall, et al.. (2020). Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy. Molecular Therapy. 28(10). 2252–2270. 30 indexed citations
9.
Innamarato, Patrick, et al.. (2020). Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells. The Journal of Immunology. 205(10). 2893–2904. 8 indexed citations
10.
Mullinax, John E., MacLean Hall, Sangeetha Prabhakaran, et al.. (2018). Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Frontiers in Oncology. 8. 44–44. 75 indexed citations
11.
Poch, Michael, MacLean Hall, Krithika N. Kodumudi, et al.. (2018). Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. OncoImmunology. 7(9). e1476816–e1476816. 35 indexed citations
12.
Cameron, Alan C., et al.. (2018). VASCULAR EFFECTS OF ANTI-CANCER CISPLATIN THERAPY. Journal of Hypertension. 36(Supplement 1). e99–e99.
13.
Poch, Michael, MacLean Hall, Krithika N. Kodumudi, et al.. (2017). Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.. Journal of Clinical Oncology. 35(7_suppl). 142–142. 3 indexed citations
14.
Hall, MacLean, Hao Liu, Mokenge P. Malafa, et al.. (2016). Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. Journal for ImmunoTherapy of Cancer. 4(1). 61–61. 116 indexed citations
15.
Sarnaik, Amod A., MacLean Hall, John E. Mullinax, et al.. (2015). Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma. Journal for ImmunoTherapy of Cancer. 3(S2). 1 indexed citations
16.
Hall, MacLean, John E. Mullinax, Erica Royster, et al.. (2015). Expansion and characterization of tumor-infiltrating lymphocytes from human sarcoma. Journal for ImmunoTherapy of Cancer. 3(S2). 2 indexed citations
17.
Wang, Wenshi, Daohai Yu, Amod A. Sarnaik, et al.. (2012). Biomarkers on melanoma patient T Cells associated with ipilimumab treatment. Journal of Translational Medicine. 10(1). 146–146. 86 indexed citations
18.
Sarnaik, Amod A., Maria Jure–Kunkel, MacLean Hall, et al.. (2012). Costimulatory effect of agonistic 4-1BB antibody on proliferation and effector phenotype of tumor-infiltrating lymphocytes in melanoma.. Journal of Clinical Oncology. 30(15_suppl). 2511–2511. 2 indexed citations
19.
Paraiso, Kim H.T., Inna V. Fedorenko, Liliana Cantini, et al.. (2010). Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. British Journal of Cancer. 102(12). 1724–1730. 227 indexed citations
20.
Sarnaik, Amod A., Bin Yu, Daohai Yu, et al.. (2010). Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma. Clinical Cancer Research. 17(4). 896–906. 157 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Earl Avramis Breakdown of academic impact, for papers by A. Ribas Breakdown of academic impact, for papers by Virginia Picasso Breakdown of academic impact, for papers by Lisa Cucolo Breakdown of academic impact, for papers by Megan Duggan Breakdown of academic impact, for papers by Teofila Seremet Breakdown of academic impact, for papers by John Jakob Breakdown of academic impact, for papers by Viviana Bozón Breakdown of academic impact, for papers by Petranel T. Ferrão Breakdown of academic impact, for papers by Marcello Curvietto
Rankless by CCL
2026